23rd SCIENTIFIC WORKING GROUP ON THE STANDARDISATION OF
GENOME AMPLIFICATION TECHNIQUES FOR THE SAFETY TESTING OF
BLOOD, TISSUES AND ORGANS FOR BLOOD BORNE PATHOGENS
SoGAT Blood Virology Meeting
Vilnius, Lithuania - 16-17 April 2012
AGENDA
Each speaker will be allocated 10-15 minutes for each presentation including 2-3 minutes for questions.
Speakers are requested to keep the presentation concise and not to include too much background
information. Approximately 30 minutes is set aside at the end of each session to allow for further
discussion of issues which are relevant to that session.
DAY 1
MONDAY 16 APRIL 2012
07:45-08:30
Registration
08:30-08:40
Welcome Address
Introduction: Stephen Inglis, Director, NIBSC, UK
Welcome Address: Saulius Caplinskas, Director, Centre for Communicable Diseases, Lithuania
08:40-09:00
SESSION 1
Overview of blood virology testing in the Baltic States
Saulius Caplinskas, Centre for Communicable Diseases, Lithuania
09:00-11:00
SESSION 2 - International Standard Development
Chair: Clare Morris
Overview on the development of WHO International Standards
Philip Minor, NIBSC, UK
Development of the 2nd HIV Genotype Panel
Clare Morris, NIBSC, UK
Development of a Dengue Virus Reference Panel
Maria Rios, CBER, USA
Update on the 1st Chikungunya Virus RNA Reference Panel
Maria Rios, CBER, USA
Update on West Nile Reference Reagents
Maria Rios, CBER, USA
Progress update on the development of a Hepatitis D virus International Standard
Micha Nuebling, PEI, Germany
Round Table Discussion
11:00-11:30
Tea/Coffee Break
Page 1 of 3
11:30-12:30
SESSION 3 - Problems Occurring with Genotype Detection, (part I)
Chair: Neil Berry
Overview of deep sequencing technology to identify viral variants, experiences of sequencing genotypes
Neil Berry, NIBSC, UK
Novel generic method for developing Quantitative NAT Assays
Speaker TBA, Roche, USA
Update on the HIV Variants Panel
Indira Hewlett, CBER, USA
12:30-14:00
Lunch (possible SOGAT Committee Meeting)
14:00-15:00
SESSION 3 - Problems Occurring with Genotype Detection, (part II)
Chair: Neil Berry
HCV Genotype experience from a panel manufacturer
Pat Garrett, SeraCare, USA
Correlation between HBV infectivity and detection of HBV genome variants
Jean-Pierre Allain, University of Cambridge, UK
Development of an HEV genotype panel
Micha Neubling, PEI, Germany
Pilot study results of Global NIH HIV Variants Study
Mark Manak, MHRP, USA
General Questions from Session 3
15:00-15:30
Tea/Coffee Break
15:30-17:30
SESSION 4 - External Quality Assurance Scheme Panels
Chair: Karen Cristiano
EQA Programme for WNV: The Italian experience
Karen Cristiano, ISS, Italy
ISS EQA panel for Tri NAT (HCV, HIV and HBV)
Karen Cristiano, ISS, Italy
Genotype issues with EQA Panels
Vivienne James, HPA, UK
EDQM HIV, HCV and B19 NAT PTS studies in 2011
Marie-Laure Hecquet, EDQM, France
NRL EQAS for Donor Screening
Giuseppe Vincini, National Reference Laboratory, Australia
HCV genotyping, experiences from INSTAND EQA
Heinz Zeichhardt, National Reference Centre for HCV, Germany
Round Table Discussion of Sessions 3 and 4
17:30
END OF DAY 1
Page 2 of 3
DAY 2
TUESDAY 17 APRIL 2012
08:30-10:30
SESSION 5 - Overview of Issues Surrounding Established Standards
Chair: Philip Minor
Overview of the use of Biological Standards
John Saldanha, Roche, USA
Development of a nucleic acid standard based on SI units
Marcia Holden, NIST, USA
Commutability - Report back from WHO meeting to be held February 2012
Philip Minor, NIBSC, UK
Stability of 4th HCV IS - Is a 5th required?
Philip Minor, NIBSC, UK
Stoppered vial integrity
Clare Morris, NIBSC, UK
10:30-11:00
Tea/Coffee Break
11:00-12:45
SESSION 6 - Regulatory Issues
Chair: Micha Nuebling
NAT implementation guidelines: Time for an update?
Albrect Groner, CSL Bering, Germany
Update of NAT screening policy in the US
Indira Hewlett, CBER, USA
Update on NAT screening policy in Europe
Micha Neubling, PEI, Germany
Update on Japanese guidelines for NAT
Yoshiaki Okada, National Institute of Infectious Diseases, Japan
Round Table Discussion
12:45-13:15
SESSION 7 - Summing Up
Key elements discussed and forward action plan
John Saldanha, Roche, USA
Audience Comments
13:15
END OF WORKSHOP
Page 3 of 3